Good-Lite’s CSV-1000 Test Instrument Viewer is considered the gold standard for contrast sensitivity and glare testing

Medix21 is New Zealand’s new distributor for US company Good-Lite’s suite of visual acuity testing tools and vision screening products.

The team is expanding Medix21’s offering in the optometry and orthoptic market, said Camille Furnandiz, surgical sales manager. “Starting out with Fresnel prisms from Optego in early 2024, we were really excited to round the year off with Good-Lite coming on board. Established in 1930, Good-Lite’s products are the gold standard and they are the premier maker of visual acuity light boxes, eye charts, vision therapy tools and diagnostic accessories.”

Having repeatedly been asked by customers for Good-Lite products or their equivalent, Furnandiz said they became aware of the need for easy access to the company’s range. “Good-Lite was very responsive to us working together to give their products more presence and accessibility in the New Zealand market. With this agreement in place, there is no need for bulk purchasing to access Good-Lite’s distributor pricing,” she said. “This means we can order in one or 10 items for a customer at any time.”

When the right products come along, Medix21 is open to further expanding its optometry and orthoptic offerings, Furnandiz said.

High-strength atropine drop now in NZ

Bringing yet more choice to the New Zealand ophthalmic market, Medix21 is now offering Entod Pharmaceutical’s Myatro preservative-free, low-dose atropine eyedrops for treatment of myopia. The range – 0.01%, 0.025% and 0.05% – is available through CDC Pharmaceuticals as a section 29 medication (allowing supply of unapproved medicines to medical practitioners for the treatment of specific patients) at the wholesale list price of $36.30.

The Myatro range gives the additional option of higher dose strengths in 0.025% and 0.05% weight per volume as recommended by the LAMP study, said Furnandiz. “While we don’t know what mark-up pharmacies will add yet, we hope that Myatro will provide savings over the compounded version that is currently available in New Zealand.”

Medix21 is seeking MedSafe approval for the Myatro range and will then work with Pharmac for funding.